Common Drug Review *

Submission Status

Product: Abilify

Generic Name: aripiprazole

Manufacturer: Bristol-Myers Squibb (BMS)

Submission Type: Request for Advice

Date Submission Received: 2011-Mar-29 **Date NOC Issued:** 2009-Jul-09

Targeted CEDAC Meeting: 2011-Sep-21 **Priority Review Granted:** Not Requested

	Phase	Target Time (Business Days)	Target Date**	Actual CDR Date	Comments
1	CADTH Request for Advice Assessment complete	10	2011-Apr-12	2011-Apr-12	- 2011-Mar-30: Manufacturer informed of request for advice - Information or comments due 2011-Apr-15
2	CADTH Reviewers' Reports or other document sent to Manufacturer	45	2011-Jun-21	2011-May-03	- New due date report to manufacturer: 2011-May-3
3	Comments from Manufacturer on Reviewers' Reports Received by CADTH	7	2011-Jun-30	2011-May-12	- New due date for comments from manufacturer: 2011-May-12
4	CEDAC Meeting		2011-Sep-21	2011-Jun-15	- 2011-June-15: New CEDAC Meeting date
5	CEDAC Recommendation or Response to Request for Advice sent to Drug Plans, ACP and Manufacturer	5 to 7	2011-Sep-28	2011-Jun-24	- New due date for CEDAC Recommendation or Response to Request for Advice sent to Drug Plans, ACP and Manufacturer: 2011-Jun-22 - New due date for CEDAC Recommendation or Response to Request for Advice sent to Drug Plans, ACP and Manufacturer: 2011-Jun-24
	OR				
6 (a)	Embargo Period*** Manufacturers may make a Request for Reconsideration and Drug Plans may make a Request for Clarification of the Recommendation	10	2011-Oct-13	2011-Jul-11	- New due date for Embargo Period: 2011-Jul-7 - New due date for Embargo Period: 2011-Jul-11
	OR				
6 (b)	No Embargo Period if Request for Advice does not result in a Revised Recommendation				
7 (a)	Final Recommendation sent to Drug Plans, ACP, and Manufacturer (No Requests for Clarification are made AND no Request for Reconsideration is made or Request for Reconsideration is Resolved)	5	2011-Oct-20	2011-Jul-18	- New due date for Final Recommendation sent to Drug Plans, ACP, and Manufacturer: 2011-Jul-18
	OR				
7 (b)	Clarification and Final Recommendation sent to Drug Plans, ACP, and Manufacturer (Clarification Requested, no Request for Reconsideration made)	5			
	OR				
7 (c)	Placed on CEDAC Agenda For Reconsideration (At Manufacturer's request)	25 Depends on Meeting Dates			
8	Final Recommendation sent to Drug Plans, ACP, and Manufacturer	5			

* Refer to the Procedure for Common Drug Review on the Common Drug Review section of www.cadth.ca for more details.
** The CDR review process is initiated AFTER a submission is deemed complete. The target dates for this report are based on the CEDAC meeting schedule, which is posted on www.cadth.ca.
*** The Recommendation and Reasons for Recommendation are to be held in confidence and not acted upon until after the CDR Directorate has issued the notice of Final Recommendation.
Reflects updates as of Thursday noon.